Sydney Jennings

Articles

FDA, EMA Grant Lu AG13909 Orphan Drug Status for Treatment of Congenital Adrenal Hyperplasia

June 24, 2025

Lundbeck announced the designation today and said it is expanding an ongoing phase I/II clinical open label trial of the investigational mAb in adults with classic CAH.

Bimagrumab + Semaglutide Highly Effective for Loss of Fat, Preservation of Muscle in Phase 2b BELIEVE Trial

June 24, 2025

ADA 2025: The combination of the GLP-1 RA and novel monoclonal antibody yielded 92.8% of total weight loss from fat mass and 22.1% decrease in baseline weight.

Elinzanetant Reduces Hot Flashes in HR+ Breast Cancer: Daily Dose

June 24, 2025

Your daily dose of the clinical news you may have missed.

Early Atopic Dermatitis Can Be Mild, But the Threshold for Dermatology Referral Should be Low: Mona Shahriari, MD

June 24, 2025

RAD 2025: Yale dermatologist Mona Shahriari, MD, urged primary care clinicians to refer patients with AD who don't improve to prevent cumulative emotional burden.

Orforglipron, an Investigational Oral GLP-1, Cuts HbA1c and Body Weight in People With T2D

June 23, 2025

ADA 2025: Orforglipron lowered HbA1C by an average of 1.3% to 1.6% across doses, with improvements seen as early as 4 weeks, in a phase 3 trial.

Primary Care-Led Weight Management Intervention Prevents Weight Gain and Enhances Revenue: New Research

June 23, 2025

ADA 2025: An intervention to emphasize weight-related care in primary care settings eliminated weight gain at the population level, researchers report.

Weight Cycling Ups Risk for Heart Failure by 50%, Other Metabolic Diseases by Up to 30%: New Data

June 23, 2025

Weight cycling significantly raises heart failure and metabolic disease risks, independent of baseline overweight, underscoring the importance of stable weight strategies.

Once-Weekly Insulin Efsitora Comparable to Daily Glargine for Hyperglycemia in Adults with Type 2 Diabetes

June 23, 2025

ADA 2025: Insulin efsitora proved noninferior to daily insulin glargine for reducing HbA1c, resulted in fewer episodes of hypoglycemia, and required fewer dose adjustments.

FDA Approves Clesrovimab for RSV LRTD Prevention in Infants: Daily Dose

June 23, 2025

Your daily dose of the clinical news you may have missed.

5 Late-Breaking Clinical Trials in Obesity to Watch at the ADA 85th Scientific Sessions, June 20-24, 2025

June 20, 2025

Advances in obesity pharmacotherapy will be the focus of numerous late-breaking science sessions at ADA 2025; snapshots of 5 studies follow.